Apogee Therapeutics (APGE) Common Equity (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Common Equity data on file, last reported at $1.3 billion in Q1 2026.

• On a quarterly basis, Common Equity rose 86.5% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 86.5% increase from a year earlier, with the FY2025 full-year figure at $903.9 million, up 26.1% from the prior year.
• Common Equity for Q1 2026 stood at $1.3 billion, up from $903.9 million in the prior quarter.
• Over the last five years, Common Equity for APGE reached as high as $1.3 billion in Q1 2026 and fell as low as -$64.4 million in Q2 2023.
• Historically, Common Equity has averaged $480.0 million across 5 years, with a median of $602.9 million in 2025.
• Across the five-year window, Common Equity sank 1353.08% in 2023 and jumped 1818.32% in 2024, its largest moves.
• Year by year, Common Equity stood at -$35.4 million in 2022, then soared by 1173.44% to $379.9 million in 2023, then surged by 88.67% to $716.8 million in 2024, then grew by 26.1% to $903.9 million in 2025, then surged by 38.93% to $1.3 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.3 billion in Q1 2026, $903.9 million in Q4 2025, and $586.3 million in Q3 2025.